Feeling honored to be recognized for the 3rd consecutive year on Stanford University and Elsevier’s Top 2% Scientists list. #Grateful to my incredible colleagues and mentors — thank you for your support as we keep pushing boundaries and growing together @unibo.it @eassociety.bsky.social #CvPrev

Super excited to be selected for the first IAS Inflammation Academy 🌟 Looking forward to learning, sharing ideas, and being inspired by amazing mentors and peers #CvPrev #EASSoMe @eassociety.bsky.social 🔗https://athero.org/ias-inflammation-academy/

Detailed results from the pivotal P3 Launch-HTN trial were published today in @jama.com, reinforcing lorundrostat’s efficacy in a real-world setting. Read our press release to learn more: ir.mineralystx.com/news-events/... #BloodPressure #Cardiology #Cardiosky #MLYS

Too many children w/ HeFH go undiagnosed. RCPCH has launched 2 🆓 online modules to help paediatricians & HCPs better spot and support them. Let’s close the gap in care #EASSoMe @eassociety.bsky.social 📚 Learn more & take action 👉 learning.rcpch.ac.uk/courses/mana...

🎤 First time speaking at #RiminiWellness — I shared some insights on non-pharmacological strategies for managing dyslipidemia. Thanks for the invitation and the audience’s practical questions! Science & wellness grow stronger together #RW25 #CvPrev

🚨 Heart disease kills 20M+ yearly. Most prevention? Still stuck in the past. Meet ILEP-SMILE: the 360° strategy tackling not just diet & exercise, but much more! This isn’t a guideline. It’s a global call to action! 🫀🌍 🔗 www.archivesofmedicalscience.com/A-360-Perspe... 🌐 #INPST #PublicHealth

Had the pleasure of delivering a talk at the ANCE Interprovincial Congress on CV prevention & dyslipidemia management in low-risk patients. Empowering 👫 today means healthier tomorrows—for them and the healthcare system. Grateful for the warm welcome! #EASSoMe @eassociety.bsky.social

Great to have Prof. Jung Hyun Choi with us in Bologna during her journey from South Korea to Milan for the ESH Annual Congress. A meaningful exchange ahead of #ESH2025 — and a perfect occasion to let her try tagliatelle al ragù! 🇮🇹🍝 @afgciceromd.bsky.social @unibo.bsky.social

Novel staging system for systemic metabolic disorders! With actionable treatment

Step zero before lifestyle changes, meds, or surgery? Read the 🆕 EAS Consensus! 🔗https://doi.org/10.1093/eurheartj/ehaf314 Because being clueless isn’t a treatment strategy 😎 #EASSoMe @eassociety.bsky.social @cibiocm.bsky.social

The brand-new EAS Consensus is here—offering a game-changing, clinically actionable roadmap to tackle met disorders linked to obesity. Time to move from treating symptoms to a full-body, root-cause approach @eassociety.bsky.social @cibiocm.bsky.social #EASSoMe

#MyEAS2025 The live discussion of my case on statin intolerance at #EASCongress2025 was truly exciting! The EAS Stage was packed—much more than the photo shows—and the audience was incredibly engaged. Big thanks to everyone who joined for this rewarding discussion! @eassociety.bsky.social

#MyEAS2025 Honored to join as a panelist at #EASCongress2025 in a session on the power of SoMe in science & networking. Sharing how these platforms launched my journey into ath was truly exciting—and I hope it inspires other early-career researchers! @eassociety.bsky.social @katioorni.bsky.social

💡 Key takeaway in one line! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social Excited to share the latest breakthroughs in lipid research and clinical practice. Here’s a quick snapshot of yesterday's late-breaking findings 👇

The BROADWAY study results are out now in @nejm.org, published simultaneously with their presentation at #EASCongress2025 🙌 So if you missed Prof. Nicholls' talk—you can catch up here www.nejm.org/doi/full/10.... #EASCongress2025 #MyEAS2025 @maciejbanach.bsky.social @eassociety.bsky.social

Obicetrapib was well tolerated in the BROADWAY study. Long-term effects on CV outcomes will be evaluated in the ongoing PREVAIL trial—but current results suggest it holds considerable promise for improving lipid control in high CV risk patients #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

BROADWAY Study: Additionally, obicetrapib led to a placebo-adj 33.5% reduction in Lp(a), independent of its effects on other lipid parameters and HDL-C increase. The broader lipid effects are also very encouraging #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

BROADWAY study: Obicetrapib, added to maximally tolerated LLT in high-risk CV patients, reduced placebo-adjusted LDL-C by 32.6% at day 84 and 24% at day 365, with 51% of patients reaching LDL-C <55 mg/dL #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

The results of the TANDEM trial have been published in @thelancet.bsky.social , simultaneously with their presentation at the #EASCongress2025! Read the full article here: doi.org/10.1016/S014... @erinmichos.bsky.social @eassociety.bsky.social #MyEAS2025

While the TANDEM trial has limitations—short follow-up, mainly White participants, and no systematic CV event tracking—if approved, the fixed-dose combo could still offer a valuable new oral option for lowering LDL-C in patients on maximally tolerated LLT #EASCongress2025 @eassociety.bsky.social

Beyond LDL-C, the TANDEM trial showed very encouraging results on ApoB and a high proportion of patients reaching lipid targets. The fixed-dose combo was also well tolerated #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

The TANDEM trial: the fixed-dose combo of obicetrapib + ezetimibe cut LDL-C by nearly 50%, with over 70% of participants reaching levels below 1.4 mmol/L. A promising step forward in lipid lowering! #EASCongress2025 #MyEAS2025 @eassociety.bsky.social

Absolute pleasure to present at #EASCongress2025. Come and find me if you want to talk anything spatial, proteomics or mechanisms of vulnerable plaque! @eassociety.bsky.social

#EASCongress2025 Late Breakers - Key takeaway in one line! #MyEAS2025 Check out the slide below for a one-line summary of each late-breaking presentation — concise, clear, and all in one place 😎 @eassociety.bsky.social

Whether you're attending #EASCongress2025 remotely or in person, get 🛋️ — the Opening Ceremony is about to start! Right after, the Anitschkow Lecture by Prof. Ridker is the perfect way to kick off 4 💥 days of cutting-edge ath research and treatment @EASCongress @society_eas

The posters are up! 🙌 It’s such an exciting moment to see our research shared with the #EASCongress2025 community. Can’t wait for all the inspiring conversations and new ideas that will come from these next few days! @eassociety.bsky.social @afgciceromd.bsky.social #MyEAS2025

👟 Locked, loaded, and synced w/ Google Fit — ready to step into the #EASCongress2025 Step Challenge starting tomorrow @ 6 PM! From poster halls to ☕️ breaks, every step gets us closer to 🫀 health (and a bit of glory 😎) Let’s walk the talk — the step counter ends Wed @ 1 PM! @eassociety.bsky.social

Things I’ve learned from past @EASCongress editions: 1️⃣ The @eassociety.bsky.social app is the best way to navigate the event 2️⃣ Comfy 👟👟 are a must 3️⃣ Always have a backup charger 4️⃣ Mateusz is a big fan of treasure hunts 😎 #EASCongress2025, here we come ✈️! #EASSoMe

Let’s help the #EASCongress2025 first-timers! 🧳 What are your "never without" essentials for enjoying (and thriving at) the @EASCongress? Whether it’s a power bank, comfy shoes, or your favorite conference snack — share your #NeverWithout must-haves and let the tips roll in! @eassociety.bsky.social

Every time I fly to the @EASCongress, I face the same dilemma: do I carry the poster tube and juggle it through the airport, or fold the poster into my suitcase and risk the creases? ✈️🧳 What's your go-to solution #EASCongress2025 #EASSoME @eassociety.bsky.social

At #EASCongress2025, on May 6 at 13, I’ll be joining Alberto Mello e Silva to discuss a clinical case on statin intolerance @ the EAS Stage. It promises to be an engaging and practical session — we hope to see many of you there! @eassociety.bsky.social #EASSoMe

Which session at #EASCongress2025 are you most excited about? 👀 @eassociety.bsky.social I’ve started building my personal agenda and there’s so much to choose from! Drop your must-see picks below — I might add them to my list! 📝👇

Are you attending #EASCongress2025 too? ✈️ Let’s connect before Glasgow! Drop a comment if you’re going — and tag a colleague who shouldn’t miss it! 👇 #EASSoMe @eassociety.bsky.social

Excited to launch a new Special Issue in @CIMB_MDPI on Molecular Mechanisms and Therapeutic Advances in Hypertension Management and Vascular Health. Let’s push the field forward together 🔬! 🔗 www.mdpi.com/journal/cimb... @afgciceromd.bsky.social @mdpiopenaccess.bsky.social #CvPrev

A decade of driving change in lipidology w/ ILEP — grateful beyond words to the community that welcomed me, shaped me, and still inspires me every day. Can’t wait to celebrate in Warsaw on June 5–6 with @maciejbanach.bsky.social & the whole ILEP family #Turning10 #MilestoneBirthday

In this #AtheroTalk episode, @j_rvl shares her passion for cardiovascular prevention, familial hypercholesterolemia, and how she balances research with clinical work. Don’t miss this insightful conversation! 🎧 eas.to/ATHTalkE09S #EASSoMe @eassociety.bsky.social

So happy to see the @eassociety.bsky.social joining the Bluesky community! Looking forward to sharing ideas and staying connected in this new space ✨ #EASSoMe #CvPrev

Our study in @ATHjournal compares 23 formulas to estimate ApoB, offering affordable alternatives to direct testing. A step forward in improving CV risk assessment in low-resource settings 💡 📑 Want to learn more? Read and download the full study here: www.atherosclerosis-journal.com/article/S002...

Just back from the Italian Society of Obesity Congress #SIO in beautiful Baveno, where I was thrilled to share insights on the pre-pharmacological management of dyslipidemia. Huge thanks for the sharp questions and amazing turnout — a real boost of motivation! ⚡️ #EASSoMe #CvPrev

#AtheroTalk A new episode of my fav podcast is finally out! @FloPorsch sit down with Mate Kiss, winner of the 2023 @society_eas Young Investigator Award, to discuss his groundbreaking research on macrophages, complement C3, and atherosclerosis #EASSoMe 🎙️ eas-society.org/2025/atherot...

🚀 Just 7 days in, and the Atherosclerosis LinkedIn page is already making great strides! #ThankYou for your incredible support 🫂 🔗https://linkedin.com/company/atherosclerosis @katioorni.bsky.social #CvPrev

Wear red to be seen, to be counted, to be heard, to make an impact. At Atherosclerosis, we wear red every day 🥰 #WearRedDay #GoRedforWomen #NationalGoRedDay 🔗https://www.atherosclerosis-journal.com/

You have until January 31st to apply for the EAS Young Investigator Awards! Don’t miss this opportunity to showcase your research! 🧑‍🔬✨ #EAS2025 #EASSoMe 🔗https://eas-society.org/society-affairs-and-governance/grants-awards-prizes/young-investigator-awards-for-outstanding-publications/

Excited to share our editorial "Reducing the Global Prevalence of Cardiometabolic Risk Factors: A Bet Worth Winning"! A crucial discussion on the need for 🌎 action to tackle cardiometabolic risks Check it out here www.metabolismjournal.com/article/S002... @afgciceromd.bsky.social #CvPrev

What great news! The deadline for submitting abstracts to the #EASCongress2025 has been extended until next Monday. For those of you who missed yesterday's deadline, there's still some time to catch up 🙌 #EASSoMe 🔗 eas-congress.com/2025/abstrac...

Hello blue sky! I'm here too 💙